SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharma gets USFDA’s nod for Saxagliptin Tablets

14 Jun 2017 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza Tablets, 2.5 mg and 5 mg of AstraZeneca AB.

Onglyza Tablets, 2.5 mg and 5 mg achieved annual sales of around $518.5 million for the 12 month period ending April 2017.

The company’s current portfolio consists of 117 products authorized for distribution in the U.S. marketplace and 68 ANDA’s pending approval with the USFDA. In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharma Share Price

2222.50 -10.45 (-0.47%)
22-Apr-2026 10:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1653.80
Dr. Reddys Lab 1215.95
Cipla 1228.20
Zydus Lifesciences 927.75
Lupin 2307.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×